Suppression of testosterone production using abiraterone acetate (AA) with or without androgen deprivation therapy (ADT) in metastatic castration resistant prostate cancer (mCRPC).

被引：3
|
作者：
Jha, Gautam Gopalji
Jeff, Engle
机构：
[1] Univ Minnesota, Minneapolis, MN USA
[2] Fairview Pharm Serv, Minneapolis, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.5049
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5049
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Abiraterone acetate (AA) plus prednisolone (P) for metastatic castration-resistant prostate cancer (mCRPC) with early progression or non-response to androgen deprivation therapy (ADT)
    Arai, G.
    Ogi, M.
    Kobayashi, K.
    Okuno, N.
    Takahara, T.
    Fukushima, K.
    Yoshizawa, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [2] ABIRATERONE ACETATE (AA) plus PREDNISOLONE (P) FOR METASTATIC CASTRATION- RESISTANT PROSTATE CANCER (MCRPC) WITH EARLY PROGRESSION OR NO-RESPONSE TO ANDROGEN DEPRIVATION THERAPY (ADT); FINAL ANALYSIS
    Nakatsu, Hiroomi
    Maniwa, Akimitsu
    Kamiya, Naoto
    Ogi, Mizue
    Kobayashi, Hisanori
    Nakayama, Masahiko
    JOURNAL OF UROLOGY, 2018, 199 (04): : E230 - E231
  • [3] Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC)
    Efstathiou, Eleni
    Titus, Mark Anton
    Wen, Sijin
    SanMiguel, Aileen
    Hoang, Anh
    De Haas-Amatsaleh, Angela
    Perabo, Frank
    De Phung
    Troncoso, Patricia
    Ouatas, Taoufik
    Logothetis, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Abiraterone acetate (AA) with or without cabazitaxel (CBZ) in treatment of chemotherapy naive metastatic castration-resistant prostate cancer (mCRPC)
    Slovin, Susan F.
    Knudsen, Karen E.
    Halabi, Susan
    Fleming, Mark T.
    Molina, Ana M.
    Wolf, Steven Paul
    de Leeuw, Renee
    Fernandez, Celina
    Kang, Praneet
    Southwell, Traci
    Jones, Carol L.
    Fernandez, Escarleth
    Kelly, William Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [5] Indicators of clinical response to abiraterone acetate (AA) men with metastatic castration-resistant-prostate-cancer (mCRPC).
    Boegemann, Martin
    Mikah, Phillip
    Eminaga, Okyaz
    Herrmann, Edwin
    Papavassills, Philipp Marius
    Semjonow, Axel
    Krabbe, Laura-Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] A multicenter population-based experience with abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC)
    Clayton, Ravinder
    Heng, Daniel Yick Chin
    Wu, Jackson S. Y.
    Zielinski, Rob
    North, Scott A.
    Emmenegger, Urban
    Hotte, Sebastien J.
    Al-Shamsi, Humaid Obaid
    Chen, Leo
    Eigl, Bernhard J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [7] The effects of enzalutamide (ENZA) in combination with abiraterone acetate (AA) in patients with bone metastatic castration resistant prostate cancer (mCRPC)
    Efstathiou, E.
    Titus, M.
    Wen, A. S.
    San Miguel, A.
    Hoang, A.
    De Haas-Amatsaleh, A.
    Perabo, F.
    Phung, D.
    Troncoso, P.
    Logothetis, C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S680 - S681
  • [8] Outcomes of prechemotherapy (pCHT) abiraterone (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after androgen deprivation therapy (ADT) plus docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a hospital-based registry.
    Francini, Edoardo
    Gray, Kathryn P.
    Evan, Carolyn
    Kaymakcalan, Marina D.
    Shaw, Grace Katherine
    Kantoff, Philip W.
    Taplin, Mary-Ellen
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate
    Di Stefano, Rosario F.
    Tucci, Marcello
    Turco, Fabio
    Samuelly, Alessandro
    Bungaro, Maristella
    Pisano, Chiara
    Vignani, Francesca
    Gallicchio, Mara
    Scagliotti, Giorgio V.
    Di Maio, Massimo
    Buttigliero, Consuelo
    PROSTATE CANCER AND PROSTATIC DISEASES, 2021, 24 (03) : 812 - 825
  • [10] Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate
    Rosario F. Di Stefano
    Marcello Tucci
    Fabio Turco
    Alessandro Samuelly
    Maristella Bungaro
    Chiara Pisano
    Francesca Vignani
    Mara Gallicchio
    Giorgio V. Scagliotti
    Massimo Di Maio
    Consuelo Buttigliero
    Prostate Cancer and Prostatic Diseases, 2021, 24 : 812 - 825
12345